Literature DB >> 29111380

Hypoxia-inducible factor 1Α may regulate the commitment of mesenchymal stromal cells toward angio-osteogenesis by mirna-675-5P.

Viviana Costa1, Lavinia Raimondi2, Alice Conigliaro3, Francesca Salamanna4, Valeria Carina2, Angela De Luca2, Daniele Bellavia2, Riccardo Alessandro5, Milena Fini4, Gianluca Giavaresi6.   

Abstract

BACKGROUND AIMS: During bone formation, angiogenesis and osteogenesis are regulated by hypoxia, which is able to induce blood vessel formation, as well as recruit and differentiate human mesenchymal stromal cells (hMSCs). The molecular mechanisms involved in HIF-1α response and hMSC differentiation during bone formation are still unclear. This study aimed to investigate the synergistic role of hypoxia and hypoxia-mimetic microRNA miR-675-5p in angiogenesis response and osteo-chondroblast commitment of hMSCs.
METHODS: By using a suitable in vitro cell model of hMSCs (maintained in hypoxia or normoxia), the role of HIF-1α and miR-675-5p in angiogenesis and osteogenesis coupling was investigated, using fluorescence-activated cell sorting (FACS), gene expression and protein analysis.
RESULTS: Hypoxia induced miR-675-5p expression and a hypoxia-angiogenic response, as demonstrated by increase in vascular endothelial growth factor messenger RNA and protein release. MiR-675-5p overexpression in normoxia promoted the down-regulation of MSC markers and the up-regulation of osteoblast and chondroblast markers, as demonstrated by FACS and protein analysis. Moreover, miR-675-5p depletion in a low-oxygen condition partially abolished the hypoxic response, including angiogenesis, and in particular restored the MSC phenotype, demonstrated by cytofluorimetric analysis. In addition, current preliminary data suggest that the expression of miR-675-5p during hypoxia plays an additive role in sustaining Wnt/β-catenin pathways and the related commitment of hMSCs during bone ossification. DISCUSSION: MiR-675-5p may trigger complex molecular mechanisms that promote hMSC osteoblastic differentiation through a dual strategy: increasing HIF-1α response and activating Wnt/β-catenin signaling.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypoxia; mesenchymal stromal cells; miR-675-5p; osteoblast commitment; regenerative medicine

Mesh:

Substances:

Year:  2017        PMID: 29111380     DOI: 10.1016/j.jcyt.2017.09.007

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  12 in total

Review 1.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

Review 2.  Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.

Authors:  Nádia de Cássia Noronha; Amanda Mizukami; Carolina Caliári-Oliveira; Juçara Gastaldi Cominal; José Lucas M Rocha; Dimas Tadeu Covas; Kamilla Swiech; Kelen C R Malmegrim
Journal:  Stem Cell Res Ther       Date:  2019-05-02       Impact factor: 6.832

3.  MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation.

Authors:  Viviana Costa; Valeria Carina; Lavinia Raimondi; Angela De Luca; Daniele Bellavia; Alice Conigliaro; Francesca Salamanna; Riccardo Alessandro; Milena Fini; Gianluca Giavaresi
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

4.  Glycolysis reprogramming in cancer-associated fibroblasts promotes the growth of oral cancer through the lncRNA H19/miR-675-5p/PFKFB3 signaling pathway.

Authors:  Jin Yang; Xueke Shi; Miao Yang; Jingjing Luo; Qinghong Gao; Xiangjian Wang; Yang Wu; Yuan Tian; Fanglong Wu; Hongmei Zhou
Journal:  Int J Oral Sci       Date:  2021-03-25       Impact factor: 6.344

5.  How miR-31-5p and miR-33a-5p Regulates SP1/CX43 Expression in Osteoarthritis Disease: Preliminary Insights.

Authors:  Viviana Costa; Marcello De Fine; Valeria Carina; Alice Conigliaro; Lavinia Raimondi; Angela De Luca; Daniele Bellavia; Francesca Salamanna; Riccardo Alessandro; Giovanni Pignatti; Milena Fini; Gianluca Giavaresi
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

6.  BMSC-Exosomes Carry Mutant HIF-1α for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects.

Authors:  Chenting Ying; Rui Wang; Zhenlin Wang; Jie Tao; Wenjing Yin; Jieyuan Zhang; Chengqing Yi; Xin Qi; Dan Han
Journal:  Front Bioeng Biotechnol       Date:  2020-11-19

7.  Osteoblast-derived EGFL6 couples angiogenesis to osteogenesis during bone repair.

Authors:  Kai Chen; Shijie Liao; Yicheng Li; Haibo Jiang; Yun Liu; Chao Wang; Vincent Kuek; Jacob Kenny; Boxiang Li; Qian Huang; Jianxin Hong; Yan Huang; Shek Man Chim; Jennifer Tickner; Nathan J Pavlos; Jinmin Zhao; Qian Liu; An Qin; Jiake Xu
Journal:  Theranostics       Date:  2021-09-27       Impact factor: 11.556

8.  Hypoxia-Induced miR-675-5p Supports β-Catenin Nuclear Localization by Regulating GSK3-β  Activity in Colorectal Cancer Cell Lines.

Authors:  Laura Saieva; Maria Magdalena Barreca; Chiara Zichittella; Maria Giulia Prado; Marco Tripodi; Riccardo Alessandro; Alice Conigliaro
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

Review 9.  Substantial Overview on Mesenchymal Stem Cell Biological and Physical Properties as an Opportunity in Translational Medicine.

Authors:  Heba Abdelrazik; Emanuele Giordano; Giovanni Barbanti Brodano; Cristiana Griffoni; Elena De Falco; Alessandra Pelagalli
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

Review 10.  Bone Regeneration Improves with Mesenchymal Stem Cell Derived Extracellular Vesicles (EVs) Combined with Scaffolds: A Systematic Review.

Authors:  Federica Re; Elena Gabusi; Cristina Manferdini; Domenico Russo; Gina Lisignoli
Journal:  Biology (Basel)       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.